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ABBREVIATIONS USED IN LITERATURE REVIEW 
ACC  Acetyl coenzyme A carboxylase 
AMPK              AMP activated protein kinase 
aPKC  Atypical protein kinase C 
AS160  Akt substrate of 160 kDa 
CKD  Chronic kidney disease 
CVD  Cardiovascular diseases 
DC  Dendritic cells 
DM     Diabetes mellitus 
DN                    Diabetic nephropathy 
DN SHIP2  Dominant negative forms of SHIP2 
DP-BB  Diabetes prone biobreeding 
DPP-4  Dipeptidyl peptidase 4 
DR                    Diabetic retinopathy 
EH  Essential hypertension 
FOXO  Forkhead family box O 
GADA              Glutamic acid decarboxylase antibodies  
GDM     Gestational diabetes mellitus 
GK  Goto-kakizaki 
GLP-1 RA  Glucagon like peptide -1 receptor agonists 
GLUT4  Glucose transporter 4 
GP  Gastroparesis 
GSK3β  Glycogen synthase kinase 3β   
HbA1c              Hemoglobin A1c 
HOMA  Homeostatic model assessment 
IFG  Impaired fasting glycemia 
IR  Insulin receptor 
IRS     Insulin receptor substrate 
IRS-1                Insulin receptor substrate-1 
ISA                   Insulin sensitizing agents 
LADA  Latent autoimmune diabetes in adults 
LBDD               Ligand based drug discovery 
MALA  Metformin associated lactic acidosis 
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MAPK  Mitogen activated protein kinase 
MARD              Mild age-related diabetes 
mGPD  Mitochondrial glycerophosphate dehydrogenase 
MOD  Mild obesity related diabetes 
MONW  Metabolically obese normal weight 
mTOR  Mammalian target of rapamycin 
NOD                 Non-obese diabetic 
PDK1  3-phosphoinositide -dependent protein kinase 1 
PI-3,4,5-P3/PIP3 Phosphatidylinositol-3,4,5-triphosphate  
PI-3,4-P2/PIP2          Phosphatidylinositol-3,4-biphosphate 
PI3K                 Phosphatidylinositol (PI) 3-kinase 
PI-4,5-P2          Phosphatidylinositol-4,5-biphosphate 
PKB  Protein kinase B 
PPARs              Peroxisome proliferator activated receptors 
PRD                  Proline rich domain 
PTEN                Phosphatase and tensin homolog on chromosome 10 
RABGAP          Rab- GTPase activating protein 
SAID  Severe autoimmune diabetes 
SAT                   Subcutaneous adipose tissue 
SGLT2   Sodium glucose cotransporters 2 
SHIP2   Src homology 2 domain containing inositol 5-phosphatase 2 
SHR   Spontaneously hypertensive rats 
SIDD   Severe insulin deficient diabetes 
SIRD   Severe insulin resistant diabetes 
T1DM      Type1 diabetes mellitus 
T2DM      Type2 diabetes mellitus 
TBC1D4   RABGAP TBC1 domain family member 4 
TSC1/2   Tuberous sclerosis protein 1/2 
TZDs  Thiazolidinediones 
 
 
 
6 
 
1. INTRODUCTION 
Diabetes mellitus (DM) is one of the major threats to human health worldwide. Insulin-dependent 
diabetes mellitus (type 1 diabetes mellitus, T1DM) and non-insulin-dependent diabetes mellitus (type 
2 diabetes mellitus, T2DM) are the two primary types of DM1. In T1DM, autoimmune destruction of 
β-cells leads to outright deficiency of insulin resulting into hyperglycemia (critically high levels of 
glucose in bloodstream), whereas T2DM is associated with impaired insulin production and insulin 
resistance leading to an impaired insulin action in glucose metabolism resulting into hyperglycemia2, 
3, 4. In 2010, around 285 million people were living with DM5. In 2017, this number increased to 425 
million people worldwide, 90% of whom were living with T2DM (International Diabetes Federation-
IDF, 2017). In low- and middle-income countries, the increase in number was more prominent, and 
more frequent in men compared to women6. In addition to this, another 350 million people were 
susceptible to develop T2DM in the same year7. By 2045, the number of people (20 -79 years of age) 
with DM is projected to burgeon up to 629 million5. Moreover, gestational diabetes mellitus (GDM), 
which is diagnosed in the second or third trimester of pregnancy, affects large population of pregnant 
women worldwide2, 8. According to the report of IDF in 2017, approximately 14 % live births were 
affected by GDM.  
T2DM is primarily caused by the interplay among genetic risk factors related to 
compromised insulin secretion and insulin resistance, environmental factors such as obesity, stress, 
aging, and several other factors1,9. Due to insulin resistance and high blood glucose level, T2DM 
patient is more prone to macro vascular diseases such as hypertension, strokes, heart attack, vascular 
disease and peripheral vascular diseases, microvascular diseases such as nephropathy, retinopathy 
and neuropathy, and various forms of cancers1. Studies have shown that excessive nutrition in 
individuals susceptible to metabolic diseases causes peripheral tissues to resist insulin action and 
thereby, affect the blood glucose uptake which ultimately raises the level of blood glucose. This 
incident eventually leads to excess secretion of insulin by islet β-cells of pancreas termed as 
‘hyperinsulinemia’10,11,12. However, due to varied experimental observations, there is a debate 
whether insulin resistance is the one that causes hyperinsulinemia or vice versa. Animal studies have 
shown that chronic hyperinsulinemia is associated with reduced insulin sensitivity13, 14,15. Research 
in Lepob/ob mice has shown that insulin resistance, obesity and increased lipogenesis are preceded 
by hyperinsulinemia15, 16,17. This clearly shows that T2DM is linked to malicious complex web.  
At mechanistic level, the pathophysiology of T2DM and associated insulin resistance 
depend on a complex chain of phosphatidylinositol (PI) 3-kinase -Akt-mediated insulin signaling 
pathway in which varied perturbations such as posttranslational modifications and/or mutations in 
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insulin receptors, insulin receptor substrates (IRS) or in downstream molecules could be impetus 
behind the impairment in the pathway. Decreased phosphatidylinositol (PI) 3-kinase (PI3K)/Akt 
activities and impaired expression and function of GLUT4 glucose transporter proteins are the most 
common modifications caused in insulin resistance18. One critical factor that contributes to the 
disturbance of PI3K-Akt pathway is hyperphosphorylation of IRS proteins at Ser/Thr. It eventually 
decreases its interaction with PI3K kinase due to decreased phosphorylation at Tyr and ultimately 
reducing the phosphorylation and activation of Akt kinase19. Moreover, lipid phosphatases such as 3’ 
phosphatase PTEN (Phosphatase and tensin homolog on chromosome 10) and 5’ phosphatase SHIP2 
(the Src homology 2 domain containing inositol 5-phosphatase 2) play vital roles in negatively 
regulating insulin signaling pathway below PI3K by altering phosphatidylinositol- 3,4,5-
trisphosphate (PIP3) levels by hydrolyzing it to phosphatidylinositol-4,5-biphosphate (PI(4,5)P2) or  
phosphatidylinositol- 3,4- biphosphate (PI(3,4)P2) respectively20,21,22. Sasaoka et al (2001) have 
reported that overexpression of SHIP2 inhibits insulin activity via its 5’-phosphatase activity in L6 
myotubes, acting as a negative regulator of PI3K-Akt-mediated insulin signaling pathway23. SHIP2 
has been shown to be upregulated in the skeletal muscle of an insulin-resistant diabetic db/db mice 
model20. Also, insulin sensitizing agents such as Rosiglitazone ameliorate upregulated SHIP2 
resulting in insulin induced Akt activation marking the association of SHIP2 with insulin resistance20. 
Since scientific literature has reported the association of SHIP2 with insulin resistance, 
inhibiting the 5’ –phosphatase activity of SHIP2 could offer a new target for the treatment of T2DM 
with despaired insulin signaling. There are few SHIP2 inhibitors reported in scientific journals in 
recent years24,25,26,27,28. However, due to poor drug like properties of these inhibitors, further 
investigation is needed to identify inhibitors that can be used as medicinal drugs. 
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2. BACKGROUND LITERATURE REVIEW 
 
2.1 Diabetes and its classification  
Diabetes mellitus (DM) is defined as ‘heterogeneous disturbances of metabolism’29. Such 
disturbances are mainly the result of hyperglycemia, possibly leading to diffused vascular impairment 
and multiorgan failure30,31. The cardinal cause for this could be explained by either disturbed insulin 
secretion or disturbed action of secreted insulin hormone or by both29. DM is becoming more and 
more common health issue at global level and no longer limited to just the western lifestyle. 
According to American Diabetes Association (ADA), 2014, DM is not a single disease but consisted 
of several diseases classified by etiology and pathology, such as Type 1 diabetes mellitus (T1DM), 
Type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and the class ‘other’ which 
includes monogenic diabetes and cystic fibrosis related diabetes32,33. Insulin deficiency is the most 
common feature in different classes of diabetes syndrome mentioned above34. Among varied classes, 
T2DM affects almost 85-90 % of the population suffering from diabetes, GDM affects ~5-6% of  the 
pregnant females who in most cases show early forms of T2DM, and patients with T1DM account 
for ~5-10%32,34. Since diabetes is heterogeneous and vary significantly, the assigned type of DM to a 
patient is often misleading since it is based on the circumstances at the time of the diagnosis2. 
 Three kinds of complications are associated with diabetes: Macrovascular, 
microvascular and neurologic. Increased blood glucose is the common denominator of all the three 
kinds of complications of diabetes. Long-term prognosis of the patients with diabetes is obscure; 
however, the chances are that the individuals may develop diabetic retinopathy (DR) with possible 
vision impairment, diabetic nephropathy (DN) resulting in renal failure, and neuropathy31. Diabetic 
patients are frequently diagnosed with cerebrovascular, peripheral arterial and atherosclerotic 
cardiovascular disease and often suffer from hypertension and impaired lipoprotein metabolism33. 
Early onset atherosclerosis of the coronary arteries is common macrovascular disease among diabetic 
patients and is frequently found to be the primary cause of death of an individual with diabetes34.  
 Numerous risk factors either modifiable, such as life style of an individual, glycemic 
control, dyslipidemia, hypertension, or non-modifiable such as genomic construction, age, duration 
of diabetes, are associated with the pathogenesis of diabetes31. Hyperglycemia is a crucial determinant 
in the development of vascular complications of diabetes, both acute and chronic hyperglycemia have 
lethal effects on diabetic patients30.  
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2.1.1 Type 1 Diabetes Mellitus (T1DM)  
T1DM is a chronic autoimmune disorder involving the selective destruction of insulin-secreting 
pancreatic β cells by a β cell–specific autoimmune mechanism. It is one of the most common chronic 
disorders occurring in children and adolescents, however it can be diagnosed in adults35. β-cells are 
responsible for maintaining glucose level within a narrow physiological range by sensing glucose and 
secreting insulin. Hence, once these cells are destroyed, the maintenance of blood glucose level is 
disturbed resulting in ketoacidosis and severe hypoglycemia. Secondary complications such as renal 
failure, vision loss or heart disease could also occur as consequences. Moreover, T1DM is a 
multifactorial disease making it difficult to elucidate the pathogenesis of the disease36,37. In the 
progression of T1DM, genetic predisposition is crucial, however, the concordance rate was found to 
be only ~40% in the studies of T1DM in identical twins indicating the contribution of nongenetic 
factors in the disease development38. To understand the pathogenesis of human T1DM, the non-obese 
diabetic (NOD) mice models and diabetes prone BioBreeding (DP-BB) rat models have been 
extensively studied. It has been shown that several different immune cell types such as CD4+ and 
CD8+ T cells, B lymphocytes, macrophages, dendritic cells (DC) and β cell autoantigens are involved 
in the β-cell specific autoimmune process39. The immunologically activated CD8+ cytotoxic T cells 
along with activated CD4+ helper T cells destroy β-cells in islets. Moreover, the damage to β-cells is 
also done by granzymes, perforin, reactive oxygen species and synergistic interactions of cytokines40.  
 For T1DM, exogenous insulin administration is quite prominent therapy. However, due 
to precise dosing issues and number of injections and other issues related with the complexity of the 
disease, stem cell based β-cell replacement therapies are under consideration for the treatment of 
T1DM for its cost effectiveness41.  
 
2.1.2 Type 2 Diabetes Mellitus (T2DM)  
T2DM was earlier believed to be an exclusive adult metabolic disease, but, since the beginning of the 
21st century, it has been reported more commonly even in youth and adolescents, and occasionally in 
children42,43. It is associated with obesity and overweight. However, metabolically obese normal 
weight (MONW) individuals with insulin resistance are at higher risk of developing T2DM than 
overweight individuals without insulin resistance or metabolic disorder. The factors responsible for 
metabolic obesity in normal weight individual might possibly involve central obesity, low weight at 
birth, lack of exercise and active routine, and family history44. Hyperglycemia and altered lipid 
metabolism are important characteristics of T2DM resulting from inadequate responses of pancreatic 
islet β cells and adipose tissue to chronic fuel surfeit44. The damaged pancreatic islets and stressed 
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adipose tissues lead to elevated concentrations of inflammatory cytokines in peripheral tissues such 
as skeletal muscle and liver due to nutrient spillover. Thus, metabolic defects such as damaged islet 
cells, impairment of subcutaneous adipose tissue (SAT) expansion, enhanced production of 
endogenous glucose in the liver and peripheral insulin resistance contribute to the development of 
T2DM45,46. 
 Once hyperglycemia is present, insulin resistance is the key predictor of T2DM and 
could be a target of therapeutic interventions. At the pre-onset of T2DM, resistance to insulin leads 
to extra secretion of insulin to compensate slightly high concentration of glucose in blood, ultimately 
leading to hyperinsulinemia. When hyperinsulinemia can no longer compensate insulin resistance, 
diabetic state persists, and hyperglycemia becomes apparent in fasting and post-prandial state. 
Hyperglycemia leads to a diffuse endothelial dysfunction, micro and macrovascular complications of 
diabetes and multiorgan failure30,31. Among several mechanisms by which hyperglycemia contributes 
to vascular complications, polyol pathway is the most crucial mechanism contributing to diabetic 
complications by increasing glucose flux47. Skeletal muscle is the major site of insulin-mediated 
glucose uptake in the post-prandial state. Impaired glycogen synthesis in muscle tissues plays a 
crucial role in the development of insulin resistance. There are three rate controlling steps in the 
metabolism of muscle glucose: GLUT4 glucose transporter, hexokinase, glycogen synthase, which 
have been implicated in impaired glycogen synthesis. Intracellular impairments in glucose transport 
is the rate controlling step for glucose uptake in muscle tissues. Impaired intramyocellular fatty acid 
metabolism could lead to such defects. Through defects in intramyocellular fatty acid metabolism, 
fatty acids could lead to insulin resistance by activating a serine kinase cascade, leading to decreased 
insulin-stimulated (IRS)-1 tyrosine phosphorylation and eventually decreased activity of PI3K 
kinase, which is a key step in insulin-stimulated glucose uptake into muscle48. 
 
2.1.3 Novel classification of adult-onset DM: recent findings 
Ahlqvist et al (2018) recently described a new substratification of diabetes based on six variables: 
glutamic acid decarboxylase antibodies (GADA), age of the patient at the time of diagnosis, HbA1c 
(Hemoglobin A1c – glycated hemoglobin), BMI (Body Mass Index) and homeostatic model 
assessment (HOMA) quantifying insulin resistance and pancreatic β cell function. In their study, they 
used data from four separate populations divided into five cohorts from Sweden and Finland (Figure 
1)48 to substratify diabetes into five clusters49.  
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(A) Traditional classification-based distribution of ANDIS cohort 
 
(B) Distribution of ANDIS cohort based on k-means clustering 
       
Figure 1. Distribution of patients based on classification method by Ahlqvist et al (2018)
49
,  
images modified from the original (License to reuse the image has been obtained from Elsevier) 
LADA: latent autoimmune diabetes in adults. SAID: severe autoimmune diabetes. SIDD: severe insulin-
deficient diabetes. SIRD: severe insulin-resistant diabetes. MOD: mild obesity-related diabetes. MARD: 
mild age-related diabetes. ANDIS: All New Diabetics in Scania
49
. 
 
Cluster 1 (severe auto immune diabetes – SAID) was associated with poor metabolic control, insulin 
deficiency, presence of GADA, relatively low BMI and was found to be an early onset disease. 
Cluster 2 (severe insulin deficient diabetes - SIDD) was an early onset disease with relatively low 
BMI, poor insulin secretion and poor metabolic regulation. Cluster 3 (severe insulin resistant diabetes 
– SIRD) was associated with high insulin resistance and high BMI. Cluster 4 (mild obesity related 
diabetes – MOD) was characterized by obesity. Cluster 5 (mild age-related diabetes – MARD) was a 
late onset disease. In their study, the patients in cluster 3 were at higher risk of diabetic kidney disease 
than patients in other clusters, however, the current treatment did not differ in their prescription. 
Moreover, patients in cluster 2 were most likely to develop retinopathy. Further, they found that a 
T2DM-associated variant in the locus TCF7L2 was linked to SIDD, MOD and MARD whereas a 
T1DM-associated variant in the locus HLA (Human Leukocyte Antigen) was strongly linked to 
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SAID. The researchers could come up with two new severe forms of diabetes: SIDD and SIRD, which 
were traditionally covered under T2DM49. 
This novel classification may assist in individualized medicine – a branch of medicine that takes into 
account the genetic, environmental and lifestyle variability of individuals rather than the one-size-
fits-all strategy to treat this heterogenous disease. The key advantages are its ability to predict diabetic 
nephropathy in SIRD and retinopathy in SIDD49. The clustering in the study of Ahlqvist et al suggests 
to target insulin resistance in randomized trials and enhance insulin sensitivity in SIRD. However, 
there are no potential drugs available to enhance insulin sensitivity except pioglitazone49. 
 
2.2 Insulin Signaling 
2.2.1 PI3K/Akt mediated insulin signaling pathway and glucose uptake 
Insulin signaling network is complex and has effects on cellular metabolism, growth and 
differentiation. Muscle tissues, adipose tissues, hepatic tissues and neurons are the major sites of 
insulin action50. Insulin performs its fundamental actions by binding to insulin receptors leading to 
the activation of three major pathways: (i) The PI3K-Akt pathway responsible for glucose uptake in 
muscle cells and adipocytes, (ii) The TSC1/2-mTOR pathway important for protein synthesis and 
cellular energy homeostasis, and (iii) The RAS-MAPK (mitogen activated protein kinase) pathway 
responsible for cell proliferation, division and motility51. Insulin regulates glucose homeostasis by 
stimulating glucose transport in insulin sensitive skeletal muscle and adipose tissues. Insulin 
stimulated glucose uptake takes place primarily in skeletal muscle by the translocation of glucose 
transporters, primarily GLUT4, from intracellular locations to the plasma membrane52. The deposited 
glucose is converted into glycogen by glycogen synthase and stored as glycogen in human muscle 
fibers53. 
Insulin-dependent translocation of GLUT4 is initiated by insulin binding to insulin receptor (IR) 
which activates its tyrosine protein kinase-containing intracellular β subunit leading to the receptor 
autophosphorylation on tyrosine residues54. Subsequently, insulin receptor tyrosine kinase 
phosphorylates insulin receptor substrates – IRS1 and IRS2, leading to the activation of the 
phosphatidylinositol (PI) 3-kinase (PI3K) mediated insulin signalling pathway55 (Figure 2).  IRS 
proteins belong to a family of adaptor proteins, which recruit the catalytic subunit of PI3K kinase, 
play a role in converting the signal of tyrosine phosphorylation to the signal of lipid kinase. Class 1a 
PI3K is activated through the binding of its SRC homology 2 (SH2)-domains of the p85 regulatory 
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adaptor subunits to phosphorylated YMXM motifs in IRS-proteins. This results into the activation of 
the p110 catalytic subunit of PI3K.  
 
 Insulin                                               plasma membrane 
 
               IR 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. PI3K mediated insulin signalling pathway (simplified)
50
. 
Once insulin binds to the IR, IR is autophosphorylated and phosphorylates IRS proteins. PI3K 
associates with phosphotyrosine sites on IRSs. Subsequently, PI3K kinase converts PIP2 into PIP3 at 
the plasma membrane. This activates PDK1 that phosphorylates Akt at the Thr308. A second 
phosphorylation takes place at the Ser473 (not shown) by mTOR2. Activated Akt phosphorylates 
downstream molecules including GSKβ and TBC1D4 mediating the effects of glycogen synthesis and 
glucose uptake respectively through their inactivation by Akt 
 
Activated PI3K quickly phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), which further activates PDK-1 (3-phosphoinositide-
dependent protein kinase-1) through its PH domain. Activated PDK1 phosphorylates Akt at Thr-308. 
For the complete activation of Akt, it is further phosphorylated at Ser-473 by the mammalian target 
of rapamycin complex 2 (mTORC2). Thus, Akt is recruited to the plasma membrane from the cytosol 
and activated fully by its phosphorylation at Thr-308 and Ser-47356. Activated Akt Ser/Thr kinase 
phosphorylate downstream substrates such as the forkhead family box O (FOXO) transcription 
factors; the protein tuberous sclerosis 2 (TSC2), glycogen synthase kinase 3β (GSK3β) and Akt 
substrate of 160 kDa (AS160), also called TBC1D4 (the RABGAP TBC1 domain family member 
  
IRS
1/2 
PI3K PIP3 
 
PDK-1 
Akt/PKB 
GSKβ TBC1D4 
Glycogen synthesis Glucose uptake 
PIP2 
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4)50. Serine phosphorylation of GSK3β by Akt leads to its deactivation resulting into the activation 
of glycogen synthase and the synthesis of glycogen from glucose57. TBC1D4, a Rab-GTPase-
activating protein (RABGAP) is the Akt2 substrate responsible for GLUT4 translocation to the 
plasma membrane.  In the unphosphorylated state of TBC1D4, the target RABS are in GDP-bound 
inactive form. In muscle cells, the target RAB isoform is RAB8a166 whereas in adipocytes, RAB10 
is the target of TBC1D450. The phosphorylation of TBC1D4 by Akt kinase leads to the activation of 
RAB proteins resulting into the docking and fusion of GLUT4 vesicles to the plasma membrane. The 
recruitment of GLUT-4 vesicles to the plasma membrane is inhibited in an TBC1D4/AS160 mutant 
lacking Akt phosphorylation sites58. 
 
2.2.2 Negative regulation of insulin action by lipid phosphatases 
2.2.2.1 Phosphatase and tensin homologue on chromosome 10 (PTEN) 
In addition to the regulation of PIP3 synthesis and concentration at the plasma membrane, its 
localization and degradation is regulated by two lipid phosphatases that dephosphorylate PIP3, thus 
negatively regulating the insulin signalling (Figure 3).  
         
         Insulin                                                                                              plasma membrane 
                                 
                  IR     
                                                                                              PTEN 
                                                                                         SHIP2 
  
Figure 3. Negative regulation of PI3K mediated insulin signaling
50
: lipid phosphatases PTEN and SHIP2 
negatively regulate PI3K-Akt mediated insulin signaling pathway through their 3’- phosphatase and 5’-
phosphatase activities respectively. 
Phosphatase and tensin homologue on chromosome 10 (PTEN) is 3’-phosphatase that hydrolyses 
PIP3 into its precursor phosphatidylinositol (4,5)-biphosphate (PI(4,5) P2) and thus it is a negative 
regulator of the PI3K/Akt signalling pathway59. The inhibition of PTEN activity results into enhanced 
glucose metabolism, cell growth and survival pathway through elevated Akt activity49. On the other 
hand, in 3T3-L1 adipocytes, overexpression of PTEN leads to inhibition of GLUT4 translocation to 
the plasma membrane and hence restricts glucose uptake60.  
 
 
  
IRS
1/2 PI3K PDK-1 
PI(4,5)P2 PI(3,4,5)P3 PI(4,5)P2 PI(3,4)P2 
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2.2.2.2 Src homology 2 (SH2) domain-containing inositol 5-phosphatase 2 (SHIP2) 
Another ubiquitously expressed lipid phosphatase, Src homology 2 (SH2) domain-containing inositol 
5-phosphatase 2 (SHIP2), is a 5’-phosphatase that hydrolyses PIP3 into phosphatidylinositol (3,4)-
biphosphate (PIP2) (Figure 3). SHIP2, a 142 kDa protein encoded by INPPL1 gene, is majorly 
expressed in skeletal muscle, cardiac muscle and brain, and consists of an N terminal SH2 domain, a 
C terminal proline rich domain (PRD) and a catalytic 5’- phosphatase core domain (Figure 4)61.  
 
 
                                     N-terminal              Catalytic Core           C-terminal 
Figure 4. SHIP2: A structural illustration. 
The protein consists of an N- terminal SH2 domain, a core catalytic 5’-phosphatase domain and the C-
terminal proline-rich (PRD) domain
61
. 
 
It has histidine (His) and aspartic acid (Asp) active site pair essential for its enzymatic activity60. In 
3T3-L1 cells, SHIP2 attenuates glucose uptake62 whereas in L6 myoblasts, it inhibits phosphorylation 
of Akt and GSK-3β and thus negatively regulates insulin induced glycogen synthesis63. On the other 
hand, the expression of the dominant-negative (DN) forms of SHIP2 lacks its 5’-phosphatase activity 
to hydrolyze PIP3 in 3T3-L1 adipocytes and L6 myotubes and enhances insulin effects in glucose 
uptake and glycogen synthesis through its secondary messenger and intracellular effectors 62,63. SHIP2 
knock out enhances insulin stimulated Akt phosphorylation in mice model. However, glucose 
homeostasis and glucose tolerance remain normal64. Moreover, small molecule inhibitors of SHIP2 
ameliorate the plasma glucose level in the rodent models of diabetes and insulin resistance24. 
Clement et al (2001) generated SHIP2 knockout (SHIP2-/-) mice by deleting exons 19-29 of 
INPPL1 gene including the active Asp site. The deletion also disrupted the second gene locus Phox2a. 
As a result, they reported rapid development of lethal hypoglycemia in the mice which died within 
three days of birth. Further, they noticed increased insulin sensitivity and glucose tolerance in the 
skeletal muscles of adult mice heterozygous for SHIP2 gene (SHIP2+/-), which led to an increased 
plasma membrane translocation of GLUT4 transporter and elevated glycogen synthesis65. In the 
subsequent study of Sleeman et al. (2005), the more viable SHIP2-/- mice without the disruption of 
second locus, when fed on high fat diet, showed obesity resistance and increased insulin sensitivity64.  
Moreover, rats on high fat diet when treated with SHIP2 antisense oligonucleotides (SHIP2-AS) 
showed increased muscle insulin sensitivity and glucose tolerance indicating a critical role of SHIP2 
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in diet-induced obesity and insulin resistance66. The liver specific expression of DN SHIP2 in 
hyperglycemic-hyperinsulinemic KKAy mice model increased hepatic glycogen synthesis and 
improved glucose tolerance67. Nakatsu et al. (2010) demonstrated that SHIP2 performs a role in 
regulating the endocytic clathrin-coated pit dynamics by dephosphorylating PIP2 in addition to PIP3 
and thus defined a major site of its action which could be critical for understanding insulin signaling 
related dysregulation68.  
 
2.2.2.3 Single Nucleotide Polymorphisms (SNPs) of SHIP2  
The human INPPL1 gene is in the chromosome 11q13-14 and is associated with T2DM and metabolic 
syndromes such as hypertension and obesity. Marion et al. (2002) first reported the association of 
INPPL1 gene mutation with T2DM in rats and humans. The authors showed that Goto-Kakizaki (GK) 
and spontaneously hypertensive rats (SHR) with R1142C mutation (substitution of an arginine to a 
cysteine at amino acid 1142) are genetically prone to T2DM and/or insulin resistance due to slight 
impairment of insulin signaling. As a result, they identified a heterozygotic deletion of 16bp sequence 
containing an ATTTA pentamer of an adenylate/uridylate-rich element in the 3’-untranslated region 
(UTR) in one of the eight diabetic subjects. This mutation enhanced the gene expression levels in 
vitro, indicating their importance in mRNA stability and translation efficiency. The researchers also 
determined the frequency of Δ16bp (16 bp deletion) mutated allele in 415 diabetic subjects from the 
United Kingdom and Belgium against 567 healthy controls. They found that 9 subjects carrying the 
mutant allele belonged to the diabetic cohort, versus 3 subjects in the control group.  7 patients out of 
9 were hypertensive and 5 patients were obese69. 
 In the subsequent study, the same group of researchers identified INPPL1 SNPs 
associated with the metabolic syndrome. They resequenced the INPPL1 gene of 15.2 Kb extensively, 
including all introns and exons, in a group of 64 people and further analyzed 11 markers and 
previously published 16bp deleted sequence. They genotyped the chosen markers in 1,304 
participants from 424 British families with T2DM with confirmed Hardy- Weinberg equilibrium. In 
this Diabetes in family (DIF) study collection, hypertension was strongly associated with a group of 
3 SNPs which were also strongly associated with central obesity. Subsequently, the researchers 
genotyped the same polymorphisms in 905 French T2DM patients and 305 control individuals. There 
was no association found between the genotype and haplotype frequencies and T2DM in the case-
control study. Though, when the French diabetic patients with hypertension and without hypertension 
were compared, it showed strong link between the insertion (I) allele and hypertension. Moreover, 
the frequency of the most common haplotype was significantly higher in the French diabetic patients 
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with hypertension than those who had only hypertension but no diabetes70. However, another group 
of researchers could not confirm the significant association between essential hypertension (EH) and 
the 3 SNPs identified by Kaisaki et al. This outcome indicated that the role of SHIP2 variants could 
be specifically limited to hypertensive metabolic syndrome patients71.  
In 2005, Kagawa and colleagues identified 10 additional SNPs with a group of 
haplotypes (SNPs 1-3) and 4 missense mutations-containing SNPs (SNPs 3-6) in a cohort of 106 
T2DM patients and 100 control individuals in a Japanese population. Their analysis revealed that the 
haplotype was more frequent in nondiabetic control than diabetic patients and one SNP, L632I 
(substitution of a leucine to isoleucine at amino acid 632) was located in the 5-phosphatase domain 
of the enzyme suggesting that the mutation might protect against insulin resistance. The protective 
role of SNP3-hSHIP2 (L632I) was confirmed further in vitro, in which insulin signaling was 
enhanced and the inhibition of PIP3 signal and Akt2 phosphorylation was reduced compared to WT-
hSHIP272.  Another study in a Japanese cohort was carried out to identify SNPs on human INPPL1 
gene promoter and in 5’-UTR region73. The researchers found several SNPs in their study, among 
which 3 SNPs formed haplotypes and were associated with impaired fasting glycemia (IFG). Also, 
SNP-hSHIP2 which was present more frequently in IFG group compared to normal group showed 
increased promoter activity in vitro when inserted in luciferase reporter plasmid.  
Hao et al investigated the association between the SNPs on INPPL1 gene and T2DM 
pathogenesis in Chinese Han cohort. In their study, (+1893CC/AA) locus of INPPL1 gene in T2DM 
individuals had significantly different genotype and allele frequency compared to that between the 
healthy control individuals. Moreover, G allele of (+2945A/G) locus was found to make the T2DM 
patients more susceptible to hypertension74. More recently in 2012, Hyvönen et al investigated the 
association of INPPL1 gene SNPs with the metabolic syndrome and diabetic nephropathy in Finnish 
T1D patients. In their study, they identified two SNPs associated with the metabolic syndrome in men 
with T1D but not with diabetic nephropathy75. Interestingly, one of these SNPs was found to be 
associated with the metabolic syndrome in a British cohort analyzed earlier by Kaisaki et al70. These 
genetic studies demonstrate SHIP2 as a crucial therapeutic target of diabetes and warrant further 
research in this area. 
 
2.3 Insulin sensitizing agents/small molecules 
Oral anti-diabetic drugs can be classified into three categories: (1) Insulin sensitizing agents (ISA) 
(biguanide, thiazolidinediones), (2) Insulin secretagogues (glinide, sulfonylurea), (3) α1-glucosidase 
inhibitors76. Apart from oral drugs, incretin mimetics such as exenatide and amylin analogues such as 
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pramlintide are injectable anti-diabetic drugs. Effects of all the oral antidiabetic drugs except α1-
glucosidase inhibitors depend on the enough level of insulin or pancreatic β cell function. The insulin 
secretagogues act primarily by stimulating impaired insulin secretion and thus depend on the 
functional β cells, whereas ISA complement the action of endogenous or exogenous insulin and 
enhance inulin sensitivity to reduce the blood glucose levels. Secretagogues are less recommended 
compared to sensitizers since their effective action depends on the optimal residual β-cell function. 
Moreover, sulfonylurea in combination with insulin often results into marginal failure to produce its 
effects and the metabolic improvements and glycemic control are short-lived and transient. 
Sulphonylureas combined with insulin and glinides do not reduce HbA1c significantly (1-2%) either. 
The use of α1-glucosidase inhibitors as antidiabetic drugs is limited due to their gastrointestinal side-
effects such as stomachache, flatulence, diarrhea76.  
 Besides the established antidiabetic drugs, targeting disordered insulin signaling 
pathway is the new approach in diabetic research. One such approach is to discover novel small 
molecule inhibitors of SHIP2 enzyme which negatively regulates insulin signaling pathway64. For 
instance, Suwa et al first time reported the discovery of novel small molecule inhibitor of SHIP2, 
AS194949024.  
2.3.1 Biguanides  
For the management of T2DM, the first-line prescribed anti-diabetic drug of choice is a biguanide, 
metformin (1,1-dimethylbiguanide) (Figure 5)77,78. The extended-release tablet dosage in the initial 
stages is 500 mg per day, usually with supper. The recommended dosage increment is up to 2000 
mg79. Apart from its use in the management of T2DM, metformin has therapeutic applications in 
other disease conditions such as cardiovascular diseases (CVD), DN, polycystic ovary disease and 
cancer80. It is an antihyperglycemic agent without the risk of overt hypoglycemia found in the case 
of secretagogues such as sulfonylureas.  
 
Figure 5. Chemical structure of metformin: two coupled guanidine molecules containing additional 
substitutions
78
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It has been shown that at millimolar concentrations, metformin mediates the 
suppression of hepatic gluconeogenesis and an increase in peripheral glucose uptake by inhibiting 
mitochondrial respiratory chain complex 181,82, by activating the cellular energy sensor AMPK (AMP 
activated protein kinase)83 or by mechanisms independent of AMPK84. Madiraju et al. (2014) 
identified mitochondrial glycerophosphate dehydrogenase (mGPD) as an important molecular target 
of metformin in the liver.  Suppression of mGPD by metformin leads to the inhibition of hepatic 
gluconeogenesis82. Recently the same authors revealed that at clinically relevant plasma and liver 
concentrations of metformin, it suppresses hepatic gluconeogenesis via its inhibitory effects on 
mGPD in a redox-dependent manner in vivo. This revelation indicated the less significance of the 
previously described metformin mechanism of action involving mitochondrial complex I, AMPK-
mediated ACC inhibition or reduced ectopic lipid accumulation in liver in suppressing hepatic 
gluconeogenesis85. However, the authors did not describe the mechanism of action of metformin and 
its direct target in peripheral tissues. 
 Recently, the Lehtonen lab, where this thesis was carried out, revealed for the first time 
the mechanism of action of metformin to increase glucose uptake in peripheral tissues86. Using 
cultured myotubes and db/db mice models, the group has shown that metformin directly targets 
SHIP2’s catalytic phosphatase domain and reduces its activity, but not expression, in cultured 
myotubes and skeletal muscle cells and podocytes of diabetic mice, thereby increases insulin 
sensitivity and glucose uptake in peripheral tissues. However, they revealed that metformin does not 
reduce gluconeogenesis in the liver by suppressing SHIP2 activity, the reasons for which are unclear. 
Moreover, metformin increases GLUT4 translocation at plasma membrane87 and slows down its 
endocytosis86. In the kidneys of patients with T2DM, metformin suppresses the enhanced activity of 
SHIP2. In podocytes too, it normalizes the reduced-Akt activity induced by SHIP2 overexpression, 
thereby acting renoprotectively86. Thus, in the liver, metformin acts in a way to reduce 
gluconeogenesis82, 85, whereas in peripheral tissues, it enhances glucose uptake through suppression 
of SHIP2 activity86.   
2.3.2 Thiazolidinediones (TZDs) 
TZDs are prescribed as ISA to the diabetic patients who are not advised to take metformin as a first 
line anti-diabetic drug88. TZDs are the ligands for peroxisome proliferator-activated receptors 
(PPARs), the transcription factors that upon stimulation by TZDs modify the transcription of genes 
involved in the metabolic pathways of glucose and lipid homeostasis and thus enhance insulin 
sensitivity in muscle cells, hepatocytes and adipocytes89. TZDs cause significant reduction of HbA1c 
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(0.5 % to 1.5%). However, these drugs cause weight gain, peripheral edema and cardiac failure due 
to associated risks of fluid retention. Initially, troglitazone, rosiglitazone and pioglitazone were the 
three TZDs that FDA approved. However, later, troglitazone was withdrawn from the market due the 
associated risk of liver failure. Moreover, meta-analysis studies showed the increased risk of 
cardiovascular events associated with rosiglitazone causing its withdrawal from the market in 2010. 
Later, in 2013, after further research, the restrictions were eased by FDA. Pioglitazone is known to 
decrease the risk of stroke. Though, there is a controversy about pioglitazone’s association with 
increased risk of bladder cancer which needs further studies to clarify90. TZDs are associated with 
increased risk of bone fractures especially in women and elderly men88.  
 
2.3.3 Small molecule inhibitors of SHIP2 
PIP3 is an important secondary messenger of PI3K-Akt mediated insulin signaling pathway, and 
hydrolyzed form of this messenger by SHIP2 shifts the signaling pathway to PI(3,4)-dependent 
pathway. This indicates that SHIP2 is involved in impaired-insulin signaling pathway leading to 
several diseases including T2DM, and inhibiting its 5’ phosphatase activity by small molecule 
inhibitors might be a significant therapeutic strategy91. The synthesis of many small molecule 
inhibitors of SHIP2 has been reported including phosphorylated biphenyl 2,3 ҆,4,5 ,҆6 
pentakisphosphate (biphenyl(2,3 ҆,4,5 ҆,6)P5)25 (1), thiophene carboxamide compounds 
(AS1949490)24 (2) and (AS1938909)26 (3) by Astellas Pharma Inc. (Ibaraki, Japan), a pyrazole based 
drug NGD-6133827 (4) and a pyridin based inhibitor N-[4-(4-chlorobenzyloxy)pyridin-2-yl]-2-(2,6-
difluorophenyl)-acetamide (CPDA)28 (5) (Figure 6)91.  
 Vandeput and colleagues synthesized a series of benzene and biphenyl polyphosphates 
with more rigid phosphate regiochemistry than natural inositol phosphate and with different potency 
of inhibiting inositol 5 phosphatases. In this series, phosphorylated biphenyl compound, biphenyl 
(2,3 ,҆4,5 ҆,6) P5 was found to be the most potent inhibitor of SHIP2 with IC50= 1.8µM. Moreover, this 
inhibitor was not SHIP2 substrate or SHIP2 specific since it was also found to inhibit another 
phosphatase, type I inositol 1,4,5- triphosphate 5-phosphatase. Also, the authors did not discuss the 
selective inhibition of SHIP1 or PTEN or the structures of the inhibitors in their study25. 
 Using high-through put screening, Suwa and colleagues identified highly selective, 
potent and competent SHIP2 inhibitors, thiophene carboxamide compounds (AS1949490) and 
(AS1938909) (Figure 6) with IC50 values 0.62 µM and 0.57 µM respectively
24,26. In L6 myotubes, 
both inhibitors enhanced Akt phosphorylation, glucose consumption and glucose uptake. These 
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inhibitors were reported to enhance glucose metabolism in L6 myotubes by significantly inducing the 
mRNA expression of GLUT124,26. However, the analogues of these thiophene lead molecules with 
improved solubility, pharmacokinetic properties and cell permeabilities would need to be prepared as 
thiophenes have limited cell permeability and poor pharmacokinetic properties92. 
 
                                                  
            1. Biphenyl (2,3 ҆,4,5 ,҆6) P5                                        2. AS1949490                                        3. (AS1938909) 
                                       
                             4. NGD-61338                                                                            5. CPDA 
 
 
Figure 6. SHIP2 inhibitors: chemical structures
91
 
Using Automated Ligand Identification System (ALIS), Annis et al., (2009) identified a pyrazole 
based SHIP2 inhibitor, NGD-61338 with IC50=1.1µM, one of the most potent compounds in their 
combinatorial libraries that were screened. The inhibitor binds to the same site as its natural substrate, 
PIP327. However, the researchers did not discuss its selectivity with respect to other phosphatases, its 
effects in cells, bioavailability or in vivo toxicity studies.  
 Having no access to the crystal structure of SHIP2 catalytic domain at the time, Ichihara 
et al. released the data of a novel pyridine-based compound, CPDA using a ligand-based drug 
discovery (LBDD) strategy involving previously published NGD-61338 and AS1949490 as 
templates. Through in vitro assay, they could identify its greater potency to phosphorylate and 
enhance insulin signaling than AS1949490. In diabetic mice model, CPDA was found to ameliorate 
the impaired glucose metabolism significantly28.  
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2.3.4 Need for novel small molecule SHIP2 inhibitors 
Metformin is the first-line prescribed drug for T2DM in the absence of contraindications93. However, 
it is contraindicated in patients with chronic kidney disease (CKD), congestive heart failure and liver 
failure. Major side effects of metformin are gastrointestinal which are persistent in ~8% patients, thus 
the medication is discontinued. In patients with severe renal insufficiency, metformin may lead to 
lactic acidosis94.95. Especially in the case of patients with kidney injury and CKD, regulatory agencies 
have restricted its use. A severe metformin-associated lactic acidosis (MALA) could have lethal 
consequences due to multiple end-organ damage93. Moreover, metformin may interfere with B12 
absorption leading to vitamin B12 deficiency besides the deficiency of folic acid94,95.  
 The second-line agents of T2DM have their own contraindications and adverse effects. 
Hypoglycemia and weight gain are the primary side effects of sulfonylureas (SUs). Non-sulfonylurea 
secretagogues such as the class of medications known as glinides too may lead to hypoglycemia in 
patients with severe renal damages. TZDs are contraindicated in patients with cardiac failure and 
warrant extra caution in patients with peripheral vascular disease. Furthermore, α-glucosidase 
inhibitors have contraindications for gastrointestinal disorders besides liver cirrhosis and renal 
dysfunction. Amylin analog – pramlintide, an injectable drug, has contraindications in patients with 
gastroparesis (GP). It has also other gastrointestinal side effects.  
Among newer T2DM medications than the described above, Dipeptidyl peptidase -4 
(DPP-4) inhibitors are associated with increased risk of angioedema, upper respiratory tract infection 
(~3.0 – 9.0 % with sitagliptin) and urinary tract infection (~2.0 -5.0 % with sitagliptin)96,97,98. 
Glucagon like peptide -1 receptor agonists (GLP-1 RA) are not prescribed during pregnancy or 
lactation. The GLP-1 RA, Exenatide, is not advised to be prescribed to patients with severe renal 
damage95. Furthermore, sodium glucose co-transporters 2 inhibitors (SGLT2) are contraindicated in 
severe renal diseases. Urinary tract infections are also associated with this class of drugs. Insulin 
injections may precipitate cardiac failure94. Thus, the T2DM drugs that are already being prescribed 
have some common contraindications such as renal impairment and/or gastrointestinal problems. 
Moreover, we still lack SHIP2 inhibitors that have applicable bioavailability, solubility 
and pharmacokinetics properties. Since the first-line prescribed drug of diabetes, metformin, 
enhances glucose uptake in peripheral tissues by reducing the 5’ phosphatase activity of SHIP2 in 
cell cultures and in mice models86, more potent inhibitors targeting the activity of SHIP2 could be 
designed. Especially, the SHIP2 inhibitors that could be applicable in T2DM patients with impaired 
23 
 
kidney function are of great interest so that the patients with renal injury or impaired kidney function 
could benefit from the drugs. 
 Hence, searching for novel SHIP2 inhibitors that are specific to SHIP2, have better 
solubility, pharmacokinetic and bioavailability properties with little to no contraindications could be 
a keystone strategy in diabetes research. 
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3 AIMS OF THE STUDY 
Increasing number of patients with T2DM has necessitated the discovery of novel drug targets of 
T2DM due to lack of current optimal therapeutic options. Since insulin resistance is strongly 
associated with T2DM1 and impaired insulin signaling pathway is one of the most important factors 
behind its causes24, research in this direction could be a key strategy. SHIP2, a 5’phosphatase, is 
known to negatively regulate PI3K-Akt mediated insulin signaling pathway by hydrolyzing PIP3 to 
PIP262. Moreover, overexpression of SHIP2 is associated with insulin resistance66. Hence, inhibition 
of 5’ phosphatase activity of SHIP2 could be an important therapeutic strategy. In the last decade, 
several publications have reported identification of novel SHIP2 inhibitors 24,25,26,27,28. However, they 
still lack drug like properties. In this research scenario, 
the specific aims of the current thesis are: 
1) To identify novel small molecule SHIP2 inhibitors by testing their ability to activate the 
insulin signaling cascade in murine L6 myotubes by measuring Akt activation as an indirect 
measure of SHIP2 inhibition 
2) To test cytotoxicity of selected novel top candidate SHIP2 inhibitors in L6 myotubes 
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4 MATERIALS AND METHODS 
4.1.1 Cell Culture 
4.1.1.1 Maintenance of L6 Rat myoblasts 
L6 Rat myoblasts (CRL-1458™; ATCC®, Manassa, VA) were maintained as described earlier99 in 
high-glucose DMEM medium supplemented with 10% Fetal Bovine Serum (FBS, Sigma, St. Louis, 
MO, USA), 1% Ultraglutamine (Lonza, Basel, Switzerland) and 1% penicillin/streptomycin (P/S) 
(Sigma) in 5% CO2 at +37°C. The medium was changed every 48 hours except on weekends when 
the medium was changed early morning on Mondays. 
4.1.1.2 Splitting 10 cm continuation plate and seeding 12 well and/or 96 well plates 
The myoblasts were washed with ~10 ml sterilized PBS and then detached from the surface of dish 
by adding ~2 ml trypsin. The cells were incubated for around 4 mins at 37°C in the incubator followed 
by addition of ~7 ml fresh proliferation medium to trypsin containing cells once the cells were 
detached and free flowing in the medium. The cells were mixed well in falcon tube and centrifuged 
at 900 rpm for 4 mins. The supernatant was discarded and 4 – 5 ml fresh medium was added to the 
pellets. To count the cells, 10 µl cells were taken on each side of the Bürker chamber. For 10 cm 
continuation plate, ~20 × 104 cells on weekdays or ~18 × 104 cells on weekends were seeded in 10 
ml fresh medium.  For 12 well plates, 2.0 × 104 cells/ml/well or 1.8 × 104 cells/ml/well were seeded 
whereas for 96 well plates, 0.2 × 104 cells/100µl/well or 0.18 × 104 cells/100 µl/well were seeded 
depending on weekdays or weekends. Following formula was used to calculate the volume required 
to seed the respective number of cells.  
Required volume of cells V = (required number of cells ∕ concentration of cells), where concentration 
of cells is the number of cells counted in Bürker chamber  
The cells were split until they reached passage 8.  
4.1.1.3 Differentiation into myotubes 
Differentiation of myoblasts into myotubes for experiments in 12 well or 96 well plates was initiated 
by feeding the myoblasts a fresh differentiation medium (high glucose DMEM supplemented with 
2% FBS, 1% ultraglutamine and 1% P/S) once they reached 60-70% confluence in 12 or 96 well 
plates. The differentiation of L6 myoblasts into myotubes takes around 7-10 days depending on the 
passage number of the myoblasts. Fresh differentiation medium was fed every other day.  
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4.1.1.4 Treatment of myotubes with inhibitors 
4.1.1.4.1 Starvation of myotubes 
Once the myoblasts were completely differentiated into myotubes in 12 well plates after 7-10 days of 
differentiation period, the myotubes were starved at 37°C in starvation medium (SF medium) for 16-
20 hours. To treat the myotubes with inhibitors in the morning, the starvation was initiated in the 
previous evening. The old differentiation medium was aspirated and 1 ml fresh SF medium/well was 
added and the plate was agitated well before incubating for 16-20 hours at 37°C. 
4.1.1.4.2 Inhibitor preparation and treatment 
The novel small molecule inhibitors were prepared in DMSO by the collaborator lab and the stock 
concentration was 100mM. Before the treatment, they were diluted to 1, 10 and 25 µM concentrations 
in SF medium. For control, the same volume of DMSO as the volume of inhibitor to make 25 µM 
was diluted to fresh SF medium. After 16-20 hours of starvation period, the old medium was removed 
and 1 ml SF medium/well containing the inhibitors was added followed by incubation for 15 mins at 
~37°C.  
4.1.1.4.3 Insulin treatment 
After 15 mins of incubation with inhibitors, 10 µl of 1 µM Actrapid® human insulin (stock solution, 
Novo Nordisk Limited, Denmark) was added to each well (final concentration 10 nM) containing SF 
medium + control or inhibitors of three different concentrations and further incubated for 15 mins at 
37 °C.  The experimental scheme of the 12 well plate is following (Figure 7): 
                          3 repeats of each concentration                        Control 
 
             
 
             
 
      
            
Figure 7. Experimental scheme of the 12 well plate: inhibitor treatment 
 
25µM 10µM 1µM DMSO 
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4.2.2 Cell Lysis 
Following insulin stimulation for 15 mins, the myotube plates were immediately kept on ice and the 
cells were washed with ice-cold Phosphate-buffered saline (PBS) for three times while keeping the 
plates on ice box. It was followed by scrapping the cells into ice-cold lysis buffer [1% Nonidet P-40 
(NP40) purchased from BDH, 150mM NaCl salt, Tris-HCl, pH 7.4, 50mM NaF, 1× protease inhibitor 
cocktail (Roche (#04693116001), 1mM Na3VO4] and transferred to Eppendorf tubes to rotate for 15 
mins at 4 °C. Following rotation, the cells were centrifuged at 16,000 g at 4 °C for 10 mins and the 
supernatant was collected to measure the protein concentration.  
4.2.3 Bradford assay and sample preparation 
To prepare the samples for immunoblotting, protein concentration was measured using Bradford 
method. For this, 800 µl milli-Q water, 5 µl sample and 200 µl Bradford reagents (Bio-Rad) were 
mixed well in 1 ml plastic cuvettes. For reference reading, 5 µl of lysis buffer was mixed instead of 
cell lysate. The OD595 values of the samples were read after 5 mins of incubation on bench and 
protein concentrations in samples were calculated using a standard curve. Using the protein 
concentration, volume for 20 µg of protein was calculated and diluted with 4 × Laemmli Sample 
Buffer containing 10% β-mercaptoethanol. The samples were boiled at 100 °C for 10 mins and run 
on SDS-PAGE straight away or incubated at 100 °C for 5 mins and frozen at -20 °C to run later.  
4.2.4 Immunoblotting 
Protein samples were separated by 8% SDS-PAGE and transferred onto PVDF-FL membranes 
(Millipore, Billerica, MA) prewetted in MeOH (methyl alcohol) for 1-2 mins and equilibrated with 1 
× transfer buffer [100 ml 10× transfer buffer (19.8mM glycine + 153mM Tris), 200 ml MeOH, 700 
ml milli-Q water)] for ~2 mins, followed by a sandwich assembly of fiber pads, filter papers, gels and 
membranes as shown in figure 8. All the components were well soaked with transfer buffer and locked 
into a transfer cassette as a sandwich. Special care was taken to avoid air bubbles between the 
components of the transfer sandwich. The transfer cassette was immersed in transfer apparatus filled 
with transfer buffer. The transfer apparatus was kept in a box containing ice blocks and the transfer 
of protein samples was carried out at constant 70 V for 2 hours (or at constant 45-55 mAmp for 16-
18 hours or at constant 60 mAmp for 12 hours).   
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Figure 8. Transfer of protein samples from SDS-GEL to PVDF membrane: a sandwich assembly of 
the components of transfer cassette (Laboratory protocol) 
4.2.4.3 Immunodetection: 
Once the transfer was over, the membrane was rinsed with milli-Q water and stained with Ponceau-
S followed by the final rinse with milli-Q water to detect the protein bands. The membranes were cut 
with razor blade to get the required parts of the membranes containing the proteins of interest for 
further treatments and the rest of the membranes were discarded. The membranes were blocked in 
Odyssey blocking buffer (OBB) (LI-COR, Lincoln, NE) (diluted 1:1 with Tris Buffered Saline-TBS) 
for 1 hour at room temperature. Following blocking, the membranes were incubated with primary 
antibodies rabbit anti-phospho-Akt (Ser473) (#9271, Cell Signalling Technology, Danvers, MA) and 
mouse anti-Pan Akt (MAB2055, R&D systems, Minneapolis, MN) (1:1000 in OBB, diluted 1:1 with 
0.2% tween 20 in TBS) overnight at 4 °C. For housekeeping genes, the membranes containing the 
bands around 40-50 kDa were incubated with primary antibodies mouse anti-actin (Sigma, A3853) 
or mouse anti-α-tubulin (Sigma, T6199) (1:2000 or 1:5000 in OBB respectively). The following day, 
membranes were rinsed with TBS + 0.1% Tween 20 and washed for 15 mins three times with TBS 
+0.1 % Tween 20. After getting rid of unbound primary antibodies, the membranes were incubated 
with secondary antibodies Alexa Fluor 680 (#A10038, Invitrogen) donkey anti-mouse and/or IR800 
(#926-32213, LI-COR) donkey anti-rabbit IgGs (1:10000 in OBB, diluted 1:1 with 0.2% tween 20 in 
TBS + 0.01% SDS respectively). Detection and quantitation with an Odyssey Infrared Imager were 
done following the rinsing and washing the membranes thrice with TBS + 0.1% tween 20 for 15 mins. 
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4.2.5 Cytotoxicity test 
For alamarBlue® cytotoxicity test, 0.2 × 104 or 0.18 × 104 myoblasts/ well were seeded in 96 well 
plates using multichannel automatic pipette and differentiated into myotubes after 48 hours, which 
took around 7-10 days for myoblasts to differentiate into myotubes as described in 4.2.1. 
4.2.5.1 Preparation of inhibitor dilutions: 
Four different concentrations [50, 100, 200, 300 (µM)] of selected top candidate inhibitors were 
prepared as following: 
C300 – 4.5 µl in 1.5 ml differentiation medium 
C200 – 1 ml of C300 in 500 µl differentiation medium 
C100 – 750 µl of C200 in 750 µl differentiation medium 
C50 – 750 µl of C100 in 750 µl differentiation medium 
4.2.5.2 Treatment with inhibitors and assessment of cell viability using alamarBlue® reagent: 
As shown in figure 9, 100 µl/well of four different concentrations were added in parallel wells for 
each selected inhibitor, each having four repeats. The myotubes were incubated with inhibitors at 37 
°C for 20 hours. Following incubation, 10 µl of alamarBlue® reagent was added in each well and 
fluorescence intensity (excitation wavelength 560nm, emission wavelength 590 nm) was immediately 
measured using the Hidex Sense application, followed by the second measurement at the interval of 
45 mins and the third measurement at the interval of 60 mins. Between the measurements, the 
myotubes were incubated at 37°C. The percentage of living cells was derived by comparing it to the 
control cell. 
                                    DMSO     Inhibitor 1   Inhibitor 2 
                                 Control     µM            µM                  
                                     
Figure 9 Experimental scheme of 96 well plate for alamarBlue® cytotoxicity assay 
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5 RESULTS 
5.1 Treatment of L6 myotubes with SHIP2 inhibitors activates Akt  
Inhibition of 5’- phosphatase activity of SHIP2 enzyme increases the phosphorylation of Akt and its 
activity100. In the present study, 8 novel small molecule SHIP2 inhibitors, #160, #161, #162, #163, 
#167B, #170A, #171, #172 (due to the fact that the inhibitors are not yet secured under intellectual 
property rights, the chemical structures of the inhibitors have not been revealed in this study) were 
tested for their capacity to phosphorylate Akt to pick up the best candidate using the lysates of L6 
myotubes as described in materials and methods. These molecules were modified from the single 
candidate from the original hits found in the structure-based virtual screening86.  
 
Figure 10. Immunoblot detection of insulin-induced Akt phosphorylation in protein lysates of 
L6 myotubes using antibodies that detect phosphorylated Akt and total Akt. Actin and α-
tubulin were used for normalization.  
 
 
Figure 11. Effect of #160 on insulin-stimulated Akt phosphorylation in L6 myotubes. The level 
of Akt phosphorylation in myotubes treated with DMSO (vehicle) was set to 100% (control). A, 
B, C indicate the graphs representing the three independent experimental trials each containing 
three repeats. The L6 myotube lysates were immunoblotted (not shown) against p-Akt or pan-
Akt antibodies and the signal output was converted to percent activation by normalizing against 
house-keeping gene actin. The values are the means ± relative standard deviation of three 
experimental repeats in each trial 
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Using immunoblotting, insulin induced Akt phosphorylation on Ser473 was detected by phospho-
Akt (p-Akt) antibody at molecular weight ~60 kDa and was quantified by normalizing against 
housekeeping genes actin or α-tubulin (Figure 10)24.  
Graphs in figure 11 (A, B, C) show the three independent trials of inhibitor #160 
treatment with L6 myotubes. In the first trial (A), the Akt phosphorylation levels in the cells treated 
with 10 µM or 25µM of #160 were greater than 2-fold than in those treated with DMSO (control) 
(Figure 11, A). However, the same results could not be repeated in the subsequent trials (Figure 11, 
B, C).  
   
 
     
Figure 12 Effect of #161 on insulin-stimulated Akt phosphorylation in L6 myotubes. The level 
of Akt phosphorylation in myotubes treated with DMSO (vehicle) was set to 100% (control). A 
and B indicate the graphs representing the two independent experimental trials each containing 
three repeats. The L6 myotube lysates were immunoblotted (not shown) against p-Akt or pan-
Akt antibodies and the signal output was converted to percent activation by normalizing against 
house-keeping gene actin. The values are the means ± relative standard deviation of three 
experimental repeats in each trial 
 
In trial A of the treatment with the inhibitor #161, the phosphorylation levels of Akt 
were greater (~1.9-fold greater than control) at 10µM concentration of the inhibitor than at 1 µM 
(~1.3-fold greater than control) (Figure 12, A). However, at 25 µM concentration, the 
phosphorylation levels dropped down to ~1.6-fold compared to the control.  In the subsequent trial 
(Figure 12, B), the Akt phosphorylation was ~3-fold greater than in the control. In two trials (Figure 
12, A, B), the phosphorylation levels of Akt varied at different concentrations of the inhibitor which 
made it difficult to select the inhibitor for further analysis.  
#161  
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The Akt phosphorylation levels were ~1.5-fold greater than in the control or less than 
that in the three different experimental trials when treated with three different concentrations of #162 
(Figure 13, A, B, C).  
  
 
Figure 13. Effect of #162 on insulin-stimulated Akt phosphorylation in L6 myotubes. The level 
of Akt phosphorylation in myotubes treated with DMSO (vehicle) was set to 100% (control). A, 
B, C indicate the graphs representing the three independent experimental trials each containing 
three repeats. The L6 myotube lysates were immunoblotted (not shown) against p-Akt or pan-
Akt antibodies and the signal output was converted to percent activation by normalizing against 
house-keeping gene actin. The values are the means ± relative standard deviation of three 
experimental repeats in each trial 
 
 
 
Figure 14. Effect of #163 on insulin-stimulated Akt phosphorylation in L6 myotubes. The level 
of Akt phosphorylation in myotubes treated with DMSO (vehicle) was set to 100% (control). A, 
B, C and D indicate the graphs representing the four independent experimental trials each 
containing three repeats. The L6 myotube lysates were immunoblotted (not shown) against p-
Akt or pan-Akt antibodies and the signal output was converted to percent activation by 
normalizing against house-keeping gene actin. The values are the means ± relative standard 
deviation of three experimental repeats in each trial  
#162 
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Inhibitor #163 increased the phosphorylation of Akt in a concentration dependent 
manner. The phosphorylation levels were ~3-fold or greater than 3-fold at 25 µM concentration of 
the inhibitor compared to the control in trials A, C and D when normalized against actin (Figure 14, 
A, C, D). The result could not be repeated in one of the four trials (Figure 14, B) where increase in 
Akt phosphorylation was less than 2-fold compared to the control. Though, the inhibitor #163 was 
selected for cytotoxicity test as the results were consistent in three trials (Figure 14, A, C, D). 
The results of the trials with inhibitor #167B were highly inconsistent and could not be repeated 
(Figure 15).  
 
 
 
 
Figure 15. Effect of #167B on insulin-stimulated Akt phosphorylation in L6 myotubes. The level 
of Akt phosphorylation in myotubes treated with DMSO (vehicle) was set to 100% (control). A, 
B, C, D and E indicate the graphs representing the five independent experimental trials each 
containing three repeats. The L6 myotube lysates were immunoblotted (not shown) against p-
Akt or pan-Akt antibodies and the signal output was converted to percent activation by 
normalizing against house-keeping gene actin. The values are the means ± relative standard 
deviation of three experimental repeats in each trial 
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Treatment with Inhibitor #170A increased the phosphorylation of Akt in a concentration 
dependent manner in trial A (Figure 16, A) which was consistent with the treatment with #163 (Figure 
14, A, C, D). However, the trials could not be repeated (Figure 16, B, C). Inhibitor #170A was chosen 
nevertheless along with inhibitor #163 to assess the cytotoxicity test after discussing the results with 
the other members of the lab working on the same project.  
 
 
 
Figure 16. Effect of #170A on insulin-stimulated Akt phosphorylation in L6 myotubes. The level 
of Akt phosphorylation in myotubes treated with DMSO (vehicle) was set to 100% (control). A, 
B, C indicate the graphs representing the three independent experimental trials each containing 
three repeats. The L6 myotube lysates were immunoblotted (not shown) against p-Akt or pan-
Akt antibodies and the signal output was converted to percent activation by normalizing against 
house-keeping gene actin. The values are the means ± relative standard deviation of three 
experimental repeats in each trial  
 
In order to investigate the stability of the house-keeping gene expression under the 
current experimental conditions in L6 myotubes to get reliable results, I decided to normalize the test 
results of #171 and #172 with actin as well as α-tubulin. The graphs in figure 17 (A) shows ~ 1.75-
fold increase in the Akt phosphorylation level compared to control at 10 µM concentration of #171 
when the values were normalized against both actin and α-tubulin house keeping genes separately in 
the same blot. The graph patterns looked similar when normalized against two different house keeping 
genes. The inhibitor showed reduced Akt phosphorylation at 25 µM compared to the control when 
normalized against actin, whereas, it slightly enhanced the Akt phosphorylation at the same 
concentration compared to the control when normalized against α-tubulin (Figure 17, A). However, 
in the subsequent trial, Akt phosphorylation was enhanced at 1 µM concentration whereas at higher 
concentrations, it was lower than the control when normalized against actin or α-tubulin (Figure 17, 
B). Graphs in figure 17 (C) show ~4.5-fold increase in Akt phosphorylation at 10 µM concentration 
and ~3.5-fold increase at 25 µM concentration when normalized against α-tubulin whereas when actin 
#170A 
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was used for normalization, no differences were observed. In the fourth trial (D), the phosphorylation 
level of Akt increased ~1.25 fold only at 25 µM when the signal was normalized against actin.  
 
 
 
Figure 17. Effect of #171 on insulin-stimulated Akt phosphorylation in L6 myotubes. The level 
of Akt phosphorylation in myotubes treated with DMSO (vehicle) was set to 100% (control). A, 
B, C and D indicate the graphs representing the four independent experimental trials each 
containing three repeats. The L6 myotube lysates were immunoblotted (not shown) against p-
Akt or pan-Akt antibodies and the signal output was converted to percent activation by 
normalizing against house-keeping gene actin or α-tubulin. The values are the means ± relative 
standard deviation of three experimental repeats in each trial 
 
Akt phosphorylation level in myotubes treated with #172 was around control level or 
below control level when normalized against actin or α-tubulin (Figure 18, A). In the subsequent trial 
(B), the Akt activity was ~1.25-fold greater than in the control at 10µM when normalized against 
actin. In the same trial, at 25 µM, Akt activity was reduced compared to the control. However, 
normalization against α-tubulin showed that the phosphorylation level of Akt was lower than in the 
control at all concentrations. Interestingly, in the third trial, Akt phosphorylation was enhanced the 
most at 25µM concentration whereas none of the concentrations of the inhibitor enhanced the 
phosphorylation of Akt above the control when normalized against α-tubulin. It is noteworthy that in 
#171 
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the fourth attempt, the Akt phosphorylation level was almost 1.5-fold greater than in the control at 1 
µM when normalized against actin and almost 2.0-fold greater when normalized against α-tubulin at 
the same concentration. In comparison to 1µM concentration, higher concentrations in the fourth 
attempt did not differ much in relation to earlier attempts for the same inhibitor.  
 
 
 
Figure 18. Effect of #172 on insulin-stimulated Akt phosphorylation in L6 myotubes. The level 
of Akt phosphorylation in myotubes treated with DMSO (vehicle) was set to 100% (control) (A, 
B, C and D indicate the graphs representing the four independent experimental trials each 
containing three repeats. The L6 myotube lysates were immunoblotted (not shown) against p-
Akt or pan-Akt antibodies and the signal output was converted to percent activation by 
normalizing against house-keeping gene actin or α-tubulin. The values are the means ± relative 
standard deviation of three experimental repeats in each trial 
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5.2 Biological evaluation of inhibitors #163 and #170A using cell viability test 
 
(1) #163                                                                                   
alamarBlue® cytotoxicity assay of the inhibitor #163 
 
(2) #170A 
 
alamarBlue® cytotoxicity assay of the inhibitor #170A 
 
 
Figure 19. Analysis of alamarBlue® cytotoxicity assay of (1) #163 and (2) #170A. Graphs show 
the combined average results of the four different experimental trials for two different 
inhibitors on different days, where X-axis represents the four different concentrations 50, 100, 
200, 300 (µM) of the inhibitors and Y-axis represents viability of L6 myotubes (% of control) 
after 20 hours of incubation with inhibitors. The error bars indicate relative standard deviation 
of the four different experimental trials at each concentration value.  
 
 
Figure 19 (1) and (2) show the graphical analysis of alamarBlue® cytotoxicity assay of the inhibitors 
#163 and #170A that were selected for the assay out of the eight inhibitors studied in the present 
thesis. In total, four experimental trials were carried out for both the inhibitors on different days.  
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L6 myotubes treated with the increasing concentrations of the inhibitor #163 
proliferated above control level (>100%) indicating the inhibitor did not affect the growth of the cells 
negatively (Figure 19.1). The viability ranges from ~111% at 50 µM to ~113% at 300 µM suggesting 
that #163 is not toxic to myotubes. In Figure 19.2, the cell viability decreases with the increasing 
concentrations of the inhibitor #170A. The viability ranges from ~96% at 50 µM to ~70 % at 300µM 
(Figure 19.2). At 300 µM, the myotubes are not killed at least 50% of the initial population suggesting 
that the median lethal dose (LD50) of the inhibitor #170A is above 300 µM. Thus, the results indicate 
that since the LD50 values are greater than 300 µM for both the inhibitors, at the experimental doses 
selected for Akt activation in L6 myotubes, the inhibitors are not toxic to myotubes.  
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6. DISCUSSION 
Insulin signaling pathway is one of the most interesting research areas for novel drug 
targets of T2DM associated with insulin resistance. Moreover, an association between a novel cluster 
of T2DM known as severe insulin resistant diabetes (SIRD) and diabetic kidney disease has been 
reported in a Swedish research, though the new classification has not yet been implemented into 
clinical use49. At mechanistic level, intracellular lipid phosphatase, SHIP2, negatively regulates 
PI3K-Akt mediated insulin signaling pathway by catalyzing the hydrolysis of PIP3 to PIP2 upstream 
of Akt, and hence inhibits its activation63. In dysregulated insulin signaling pathway, this may lead to 
disease conditions including insulin resistance and T2DM. Hence, inhibition of SHIP2 might prove 
to be a beneficial treatment strategy for insulin resistance and T2DM over the traditional antidiabetic 
drugs such as ISA or insulin secretagogues. 
 Apart from the earlier genetic studies on the inhibition of SHIP263, 66, 68, 69, Suwa et al 
first time reported the discovery of novel small molecule inhibitor of SHIP2, AS1949490, by studying 
its inhibitory effects on the 5’ phosphatase activity of SHIP2 in regulating insulin signaling pathway 
and glucose metabolism in vitro and in vivo23. Their immunoblotting results indicated an increase in 
insulin-induced Akt phosphorylation in L6 myotubes treated with AS194949024. The in vivo analysis 
indicated that AS1949490 primarily inhibits SHIP2 activity in the mice liver. In the last decade after 
the report of the first SHIP2 inhibitor, AS19494190, several small molecule SHIP2 inhibitors have 
been reported in scientific literature24,25,26,27,28. However, they still lack drug like properties such as 
solubility, bioavailability, pharmacokinetics properties.  
The present thesis focuses on the novel SHIP2 inhibitors that act mainly in skeletal 
muscle tissues since it represents the primary site of insulin resistance in CKD102. Inhibitors that 
function primarily in skeletal muscle may provide a new alternative to the current treatment strategies 
for the T2DM patients suffering from CKD102,103. In this thesis, I have attempted to study the capacity 
of eight novel small molecule SHIP2 inhibitors to increase the phosphorylation of Akt using 
immunoblotting. Based on the results of immunoblotting, further I carried out cytotoxicity assay of 
the two selected inhibitors, #163 and #170A.  
 The treatment of serum-starved L6 myotubes with SHIP2 inhibitors followed by insulin 
stimulation led to the phosphorylation of Akt, which is in line with the previous reports that inhibition 
of SHIP2 activity activates insulin signaling pathway61, 62, 63. I normalized the Akt phosphorylation 
to two different house-keeping proteins, actin or α-tubulin. Akt plays a role in the regulation of actin 
organization in cytoskeleton104. Moreover, interpreting the data using a single housekeeping protein 
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actin might provide a pseudo-positive or false negative activity of Akt since house keeping proteins 
are not always very stable under experimental conditions. Besides unstable control genes, uneven 
differentiation of L6 myotubes could also contribute to the varied fold changes in Akt 
phosphorylation in separate trials.  
In 6 inhibitors out of the 8 inhibitors tested, the fold changes in Akt phosphorylation 
could not be repeated. The reason for this could be that the myoblasts were not seeded evenly in 12 
well plates in some experiments. It is to be noted that the higher the passage number, the more difficult 
it is to differentiate L6 myoblasts, which indicates that in future we need to be more careful while 
differentiating L6 myoblasts and should keep the track of timings and circadian rhythm of this 
immortalized cell line105 during splitting. In L6 myotubes treated with inhibitor #163, Akt 
phosphorylation increased almost 3-fold or above in three separate trials out of four trials in 
concentration dependent manner upon insulin stimulation and peaked at 25 µM concentration of 
#163. I normalized Akt phosphorylation against α-tubulin house-keeping protein (data not shown) in 
addition to actin to screen the effect of experimental conditions and test proteins on loading control 
proteins to alleviate erroneous results. Interestingly, upon normalization against α-tubulin, the Akt 
activation decreased drastically at 25 µM contrary to its highest activity in case of actin. This variation 
might be due to the differential stabilization of microtubules and actin organization and cell motility 
by differential expression of Akt phosphorylation104,106. The variation in normalization values could 
also be due to an experimental error. The samples for 25 µM were loaded on the edge of the blot and 
might not have been soaked evenly during incubation in the antibody dilutions leading to uneven 
signals and thus false-reduced Akt phosphorylation in the case of α-tubulin at 25µM concentration of 
#163. Treatment of myotubes with #170A in trial A also increased Akt phosphorylation almost 2-fold 
at 25 µM of the inhibitor in concentration dependent manner. Though, the results could not be 
repeated in trial B and trial C of #170A. Moreover, similar fold changes in Akt phosphorylation in 
three trials of #163 and trial A of #170A was the impetus for their selection for alamarBlue® assay 
to examine their cytotoxicity.  
The viability of the myotubes was found to be above 100% at all concentrations of the 
inhibitor #163 with ~1.13-fold increase at 300 µM. This could be due to the increased glucose 
metabolism of L6 myotubes following treatment with #16326. On contrary to the results of #163, the 
viability of L6 myotubes treated with different concentrations of #170A decreased in concentration 
dependent manner ranging from ~96% at 50 µM to ~70 % at 300µM. This shows that over the course 
of time, the conversion of resazurin to resorufin decreased and the innate metabolic activity and 
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viability of cells decreased. From this, it could be inferred that higher concentrations (above 50 µM) 
of the inhibitor #170A had toxic effects which might have triggered cell death or apoptosis, impaired 
cellular metabolism, necrosis or disruption of cellular membrane which reduced the RFU107. 
However, for both the inhibitors, the LC50 concentration is higher than the experimental doses (1µM, 
10µM, 25µM). Also, from figure 19, it could be inferred that at experimental doses of the inhibitors 
used in this study, the inhibitors are not toxic.  
In this thesis, I have first time reported the study of eight novel SHIP2 inhibitors #160, #161, 
#162, #163, #167B, #170A, #171 and #172 to analyze their capacity to activate Akt kinase following 
insulin stimulation, and based on it, further analyzed cell viability by alamarBlue® cytotoxicity assay. 
There are more inhibitors to be tested from the chemical library in addition to the inhibitors tested in 
this study. This study would be beneficial in analyzing further small molecule SHIP2 inhibitors and 
thus would be a preliminary step in the discovery of novel small molecule SHIP2 inhibitors for T2DM 
therapeutics. 
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7. CONCLUSION 
The present study was based on the role of SHIP2 enzyme as a negative regulator of PI3K-Akt 
mediated insulin signaling pathway and its association with insulin resistance and T2DM. Since 
SHIP2 is a 5’ phosphatase that hydrolyzes PIP3 to PIP2 and ultimately inhibits the phosphorylation 
of Akt and hence its activity leading to the dysregulation of insulin signaling, inhibitors of SHIP2 
could be a beneficial therapeutic strategy for the treatment of T2DM. One of the aims of this thesis 
was to identify potential SHIP2 inhibitors by their capacity to phosphorylate Akt kinase indicating 
the activation of PI3K-Akt mediated insulin signaling pathway. The immunoblot results showed ~3-
fold increase in Akt activation when myotubes were treated with inhibitor #163 and ~2-fold increase 
in Akt activation when myotubes were treated with #170A in concentration dependent manner and 
were therefore chosen further for cytotoxicity assay. The results of alamarBlue® cytotoxicity and cell 
viability assay showed that viability was above control levels when the myotubes were treated with 
#163 whereas it decreased in concentration dependent manner when treated with #170. This indicated 
that #163 did not have toxic effects on the myotubes while #170 did affect the viability of the 
myotubes. However, the LD50 value for #170 was greater than 300 µM which is above the 
experimental doses of the inhibitors. Thus, immunoblot and alamarBlue® cytotoxicity assay results 
of the present work indicate #163 and #170A to be the potential candidates out of the 8 tested SHIP2 
inhibitors.  
          All the 8 inhibitors tested in the present work showed fold changes in the Akt activation in 
varied degrees in different experimental trials. However, due to the large experimental variations, in 
future, more trials need to be performed with these inhibitors including #163 and #170A to get 
consistent results which would allow combined statistical analysis. One of the factors behind the large 
experimental variations might be the difficulty in culturing and differentiating L6 myoblasts which 
could be eased by working with this cell line over a period.  
          Apart from these 8 inhibitors, more inhibitors from chemical library need to be tested to select 
the best SHIP2 inhibitors that are potential candidate for further analysis. This thesis first time reports 
eight novel SHIP2 inhibitors #160, #161, #162, #163, #167B, #170, #171, #172 and attempts to screen 
the best out of them. This could be a significant step in the discovery of new T2DM drugs for more 
efficient, cost effective and safe treatment of the disease with least contraindications.  
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